Lung Cancer Europe (LuCE), the voice of people impacted by lung cancer in Europe, reports on recent survey results that patients with lung cancer in several European countries revealed that half did not know what a clinical trial is, and 22% had never heard of a cancer clinical trial. Sponsored by LuCE and reported on by Dr. A.M. Baird, the results were showcased at the IASLC 2019 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer.
What is LuCE?
Lung Cancer Europe, the sponsor of the study, also known as LuCE, represents the voice of people with lung cancer in Europe. LuCE aims to increase knowledge of lung cancer and provide a platform to raise awareness about disparities in detection, diagnosis, treatment, and care across Europe. The LuCE team developed the survey and qualitative interview questions based a review of relevant literature and policy sources.
The study lead, Dr. A.M. Baird, reported that the study was undertaken to gain better insight into the clinical trial experience from a patient perspective and improve clinicians’ and public health’s understanding of patient’s awareness and attitudes toward clinical trials. Dr. Baird reported, “We shared our online survey with lung cancer advocates and patients with lung cancer.” They systematically engaged with multiple stakeholders from patients to advocate organizations to pharma industry representatives.
The survey shared with patients with lung cancer across Europe and those who took part resided mostly in Poland (19.5%), Italy (18.7%), Denmark (9.9%), and Spain (9.2%).
50% of those participating in studies report a positive experience while 80% wanted to find out more about clinical trials and 75% sought it would be beneficial for patients to engage more closely with investigators in the clinical research process.
European Barriers for Lung Cancer Patients
The survey respondents identified several barriers to accessing lung cancer clinical trials: from difficulties in cross-border access to language differences and lack of accurate accessible information; to lack of patient and clinician awareness as well as disparities in access across Europe.
Dr. Baird emphasized that “the lung cancer community must work together to overcome these barriers and ensure access to clinical trials for all people impacted by lung cancer.”
Dr. A.M. Baird
Based in Ireland and on the Lung Cancer Europe Board, Dr. A.M. Baird specialized in Trinity College Dublin in the study of lung cancer.
What are the Upcoming Conferences?
The WCLC is the world’s largest meeting dedicated to lung cancer and other thoracic malignancies attracting more than 7,000 researchers/investigators, physicians, and specialists from more than 100 countries. The IASLC (International Association for the Study of Lung Cancer) is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies.